Table 12.
Use of macrolides according to habitual treatment
| Total (n = 13,932) | No. (%) | With macrolides n = 8382 (%) | Without macrolides n = 5502 (%) | p value | |
|---|---|---|---|---|---|
| Highly active antiretroviral therapy (HAART) | 13,853 | 93 (0.7) | 57 (0.7) | 36 (0.7) | 0.86 |
| Metformin | 13,860 | 1890 (13.6) | 1154 (13.8) | 736 (13.4) | 0.51 |
| Systemic corticosteroids | 13,849 | 591 (4.3) | 332 (4.0) | 259 (4.7) | 0.033 |
| Inhaled corticosteroids | 13,808 | 1304 (9.4) | 796 (9.6) | 508 (9.3) | 0.61 |
| Hydroxychloroquine | 13,855 | 70 (0.5) | 51 (0.6) | 19 (0.4) | 0.033 |
| Rapamycin (sirolimus) | 13,820 | 63 (0.5) | 41 (0.5) | 22 (0.4) | 0.44 |
| Immunosuppressants | 13,836 | 486 (3.5) | 278 (3.3) | 208 (3.8) | 0.14 |
| Biological therapy (monoclonal antibodies) | 13,851 | 180 (1.3) | 93 (1.1) | 87 (1.6) | 0.016 |